FDA Approves Rextovy: New Over-the-Counter Naloxone Nasal Spray Expands Access to Overdose Reversal

The U.S. Food and Drug Administration (FDA) has approved Rextovy (naloxone hydrochloride nasal spray 4 mg) as an over-the-counter medication for the emergency treatment of opioid overdose. This approval, announced in late June 2026, marks another significant step in expanding access to life-saving overdose reversal medications nationwide.

What Happened

Rextovy becomes the second over-the-counter naloxone product available in the United States, joining Narcan nasal spray (approved in September 2023). Manufactured by Amphastar Pharmaceuticals, Rextovy delivers a single 4 mg dose of naloxone through an easy-to-use nasal spray device designed for use by laypersons without medical training.

The FDA's approval aligns with the federal government's ongoing efforts to combat the opioid crisis through the Great American Recovery Initiative. By making another OTC option available, regulators aim to reduce barriers to naloxone access and empower more individuals to respond effectively to overdose emergencies.

Clinical Significance

Naloxone is an opioid antagonist that works by rapidly binding to opioid receptors in the brain, displacing opioid drugs and reversing the life-threatening effects of overdose, particularly respiratory depression. When administered promptly, naloxone can restore normal breathing within minutes.

Key clinical points about Rextovy:

• Single 4 mg dose: Comparable to existing OTC naloxone products
• Nasal administration: No injection required, suitable for lay use
• Rapid onset: Effects typically begin within 2-3 minutes
• Duration: Works for 30-90 minutes; multiple doses may be needed for potent synthetic opioids

What This Means for Families

The approval of Rextovy provides families with another accessible option for keeping emergency overdose reversal medication on hand. Here's what you should know:

Availability

Rextovy will be available without a prescription at pharmacies, grocery stores, and online retailers nationwide. Like other OTC naloxone products, it can be purchased by anyone regardless of whether they personally use opioids—enabling family members, friends, and community responders to be prepared.

Cost and Insurance Coverage

While OTC availability eliminates prescription barriers, cost remains a consideration. Many insurance plans, including Medicaid, cover naloxone products with little or no copay. Additionally, numerous states and local health departments distribute naloxone free through harm reduction programs and community organizations.

How to Use

Rextovy is designed for single-use administration:

1. Remove the device from packaging
2. Place the tip gently into one nostril
3. Press the plunger firmly to deliver the dose
4. Call 911 immediately—naloxone is not a substitute for emergency medical care
5. Place the person in the recovery position (on their side)
6. Monitor breathing and be prepared to administer additional doses if available

Important: Naloxone effects are temporary. Because many opioids last longer than naloxone, the person can slip back into overdose after the medication wears off. Always seek emergency medical attention.

Multiple Doses May Be Necessary

With the increasing presence of ultra-potent synthetic opioids like fentanyl and its analogs in the drug supply, multiple naloxone doses are sometimes required to reverse an overdose. Having more than one dose available—and ensuring emergency services are contacted—can be life-saving.

Harm Reduction Context

The expansion of OTC naloxone options represents a cornerstone of harm reduction strategy. Research consistently demonstrates that increased naloxone availability in communities correlates with reduced overdose mortality rates. When more people—including those who use drugs, their family members, and bystanders—have access to naloxone, more lives are saved.

This approval comes at a critical time. While national overdose death rates have begun to decline in many regions, synthetic opioids continue to drive fatalities, particularly in western states. Expanding the naloxone product market may help improve supply chain resilience and reduce costs through competition.

Where to Get Help

If you or someone you love is struggling with opioid use, help is available:

• SAMHSA National Helpline: 1-800-662-HELP (4357) — Free, confidential, 24/7 treatment referral
• Crisis Text Line: Text HOME to 741741
• 988 Suicide & Crisis Lifeline: Call or text 988
• FindTreatment.gov: Search for local treatment providers

Naloxone is a critical emergency tool, but it does not treat opioid use disorder itself. Medication-assisted treatment (MAT) with buprenorphine, methadone, or naltrexone—combined with counseling and support services—remains the gold standard for long-term recovery.

This alert was medically reviewed by Dr. Rachel Bennett, MD, a board-certified addiction medicine physician. The information provided is for educational purposes and does not constitute medical advice. In case of overdose, always call 911 immediately.